双胎妊娠晚期早产风险产前皮质类固醇随机临床试验
这项多中心随机试验纳入812名妊娠34周0天至36周5天有晚期早产风险的双胎孕妇,比较倍他米松与安慰剂对新生儿呼吸疾病的影响。主要结局(72小时内围产儿死亡或严重新生儿呼吸疾病)在倍他米松组更低(4.8% vs 7.5%;RR 0.64 [95% CI 0.42-0.98]),但新生儿低血糖风险增加。
要点
- 双胎晚期早产风险孕妇使用倍他米松可降低严重新生儿呼吸疾病风险。
- 倍他米松组新生儿低血糖风险增加(15.6% vs 11.7%;RR 1.33)。
- 主要结局和轻度呼吸疾病的降低仅见于首次给药后12小时至不足7天内分娩的新生儿。
核心结论
- 在有晚期早产风险的双胎妊娠孕妇中,产前使用倍他米松可显著降低新生儿呼吸疾病风险。
研究设计与样本
- 多中心随机临床试验,在韩国8个大学附属临床中心纳入妊娠34周0天至36周5天有晚期早产风险的双胎孕妇,2018年5月至2024年7月收集数据,按1:1随机接受2次倍他米松或安慰剂注射,采用意向性治疗分析,共812名参与者随机并分析。
主要发现
- 共分析1620名新生儿(倍他米松组818名,安慰剂组802名),两组均无围产儿死亡,严重新生儿呼吸疾病发生99例(6.1%),倍他米松组低于安慰剂组(39 [4.8%] vs 60 [7.5%];RR 0.64 [95% CI 0.42-0.98])。
- 探索性结局中,持续气道正压通气使用2小时或以上(RR 0.58 [95% CI 0.35-0.95])和新生儿暂时性呼吸增快(RR 0.47 [95% CI 0.25-0.89])在倍他米松组更低。
- 主要结局和轻度呼吸疾病风险的降低仅见于首次倍他米松给药后12小时或以上至不足7天内分娩的新生儿。
- 新生儿低血糖风险在倍他米松组增加(128 [15.6%] vs 94 [11.7%];RR 1.33 [95% CI 1.01-1.75]),但新生儿败血症或母体绒毛膜羊膜炎风险两组无差异。
临床怎么用
- 对于妊娠34周0天至36周5天有晚期早产风险的双胎妊娠孕妇,可考虑产前使用倍他米松以降低新生儿严重呼吸疾病风险。
- 用药后需关注新生儿低血糖风险增加,并注意主要获益见于首次给药后12小时至不足7天内分娩的新生儿。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Recent guidelines have recommended corticosteroid injection in women with singleton pregnancies at risk of late preterm delivery. However, the effectiveness of antenatal corticosteroid administration in women with twin pregnancies at risk of late preterm delivery has not been evaluated, and studies on this population are lacking. OBJECTIVE: To evaluate whether antenatal betamethasone administration reduces the risk of neonatal respiratory morbidity in late preterm twin neonates. DESIGN, SETTING, AND PARTICIPANTS: In this multicenter randomized trial, twin-pregnant women at 34 weeks 0 days to 36 weeks 5 days of gestation at risk of late preterm delivery were enrolled across 8 university-based clinical centers in Korea. Data were collected between May 2018 and July 2024. Intention-to-treat analysis was performed. INTERVENTION: The participants received 2 injections of betamethasone or placebo after randomization (1:1). MAIN OUTCOMES AND MEASURES: The primary outcome was perinatal death within 72 hours after birth or severe neonatal respiratory morbidity. The exploratory outcomes were mild neonatal respiratory morbidities, other neonatal respiratory morbidities, other neonatal complications, or maternal complications. RESULTS: A total of 812 participants were randomized and analyzed, with 410 in the intervention group (median [IQR] age, 35 [33-37] years) and 402 in the placebo group (median [IQR] age, 35 [32-38] years). Among 1620 neonates (818 in the intervention group and 802 in the placebo group), there were no perinatal deaths in either group, and severe neonatal respiratory morbidity occurred in 99 neonates (6.1%), with lower risk in the betamethasone group than in the placebo group (39 [4.8%] vs 60 [7.5%]; relative risk [RR], 0.64 [95% CI, 0.42-0.98]). For the exploratory outcomes, continuous positive airway pressure use for 2 hours or more (RR, 0.58 [95% CI, 0.35-0.95]) and transient tachypnea of the newborn (RR, 0.47 [95% CI, 0.25-0.89]) were lower in the betamethasone group. The risk of primary outcome and mild respiratory morbidities was reduced only in neonates delivered between 12 hours or more and less than 7 days after the first betamethasone administration. The risk of neonatal hypoglycemia was increased in the betamethasone group (128 [15.6%] vs 94 [11.7%]; RR, 1.33 [95% CI, 1.01-1.75]), but the risk of neonatal sepsis or maternal chorioamnionitis did not differ between the 2 groups. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, antenatal betamethasone administration in women with twin pregnancies at risk of late preterm delivery significantly reduced the risk of neonatal respiratory morbidity. The outcomes from this study could serve as a valuable reference in clinical management of twin pregnancies at risk of late preterm delivery. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03547791.
引用
- Lee SM, Park HS, Choi SR, et al. Antenatal Corticosteroid in Twin-Pregnant Women at Risk of Late Preterm Delivery: A Randomized Clinical Trial. JAMA Pediatr. 2025. PMID: 40982289. doi:10.1001/jamapediatrics.2025.3284
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。